|
| 38031760 | Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine. | Haematologica | 2024 |
| 38083865 | TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). | Br J Haematol | 2024 |
| 37710381 | Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. | Br J Haematol | 2024 |
| 38071734 | Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. | Am J Hematol | 2024 |
| 37706335 | Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant. | Haematologica | 2024 |
| 37688525 | Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome. | Am J Hematol | 2024 |
| 37646653 | Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy. | Haematologica | 2024 |
| 37732882 | Mast cell cytomorphology and treatment outcome in mast cell leukemia. | Am J Hematol | 2024 |
| 37772442 | Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. | Am J Hematol | 2024 |
| 37534525 | Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. | Haematologica | 2024 |
| 36377194 | Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective. | Am J Hematol | 2023 |
| 37665758 | A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. | Am J Hematol | 2023 |
| 37507408 | Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach. | Blood Cancer J | 2023 |
| 37735430 | U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. | Blood Cancer J | 2023 |
| 37537750 | IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience. | Br J Haematol | 2023 |
| 37769597 | TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia. | Leuk Res | 2023 |
| 37567878 | Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. | Blood Cancer J | 2023 |
| 37460550 | Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. | Blood Cancer J | 2023 |
| 37422593 | Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). | Leukemia | 2023 |
| 37452102 | Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. | Leukemia | 2023 |
| 37144345 | The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. | Br J Haematol | 2023 |
| 37041128 | TP53 mutation variant allele frequency of â¿¥10% is associated with poor prognosis in therapy-related myeloid neoplasms. | Blood Cancer J | 2023 |
| 37470368 | Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases. | Am J Hematol | 2023 |
| 37468452 | Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology. | Nephrol Dial Transplant | 2023 |
| 37073574 | Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. | Am J Hematol | 2023 |
| 37032414 | Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. | Blood Cancer J | 2023 |
| 36966432 | JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management. | Am J Hematol | 2023 |
| 36966263 | Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. | Leukemia | 2023 |
| 37265027 | ABO blood group type and risk of venous thrombosis in essential thrombocythemia. | Br J Haematol | 2023 |
| 37199125 | Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms. | Haematologica | 2023 |
| 36655582 | TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. | Am J Hematol | 2023 |
| 36625066 | A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. | Am J Hematol | 2023 |
| 36586169 | Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. | Leuk Res | 2023 |
| 36519330 | Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm. | Haematologica | 2023 |
| 36477202 | Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. | Blood Adv | 2023 |
| 36880366 | Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury. | Am J Hematol | 2023 |
| 36780345 | Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. | Blood Adv | 2023 |
| 36580136 | International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. | Virchows Arch | 2023 |
| 36574363 | TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. | Blood | 2023 |
| 36907917 | Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). | Blood Cancer J | 2023 |
| 36600640 | The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms. | Am J Hematol | 2023 |
| 36797234 | CPX-351 (Vyxeosâ¿¢) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. | Blood Cancer J | 2023 |
| 36599841 | Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. | Blood Cancer J | 2023 |
| 36794509 | Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. | Haematologica | 2023 |
| 36861409 | Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. | Haematologica | 2023 |
| 36861402 | Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. | Haematologica | 2023 |
| 36073516 | Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. | Haematologica | 2023 |
| 36331566 | Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. | Ann Hematol | 2023 |
| 36200127 | The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. | Am J Hematol | 2023 |
| 36349465 | Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. | Am J Hematol | 2023 |